Ceramide biosynthesis pathway enzymes

The ceramide biosynthesis pathway encompasses a series of enzymatic steps responsible for the generation of ceramides, central biomolecules in sphingolipid metabolism. The pathway includes key enzymes such as serine palmitoyltransferase (SPT), ceramide synthases (CerS), and desaturases (DES1/DEGS1), each catalyzing specific steps in ceramide synthesis. Ceramide biosynthesis is crucial for cell membrane structure, barrier function, cellular stress responses, and signaling events that regulate apoptosis, insulin sensitivity, and metabolic homeostasis. Aberrant ceramide accumulation is implicated in metabolic, cardiovascular, neurodegenerative diseases, and inflammation, making these enzymes attractive therapeutic targets. Multiple drug candidates—mostly enzyme inhibitors—have been developed for preclinical and early-stage research applications, particularly targeting CerS, SPT, and DES1. However, due to the pathway’s essential role in normal cell physiology, selective inhibition or modulation poses safety challenges, necessitating targeted approaches to minimize adverse effects and retain physiological sphingolipid functions[1][2][3][4].

Other names

Ceramide synthesis pathway enzymesSphingolipid biosynthesis pathway enzymesCeramide metabolic enzymes

Inhibition of ceramide synthase to reduce ceramide production; Inhibition of serine palmitoyltransferase (SPT) to block de novo ceramide biosynthesis; Inhibition of desaturases (e.g., DES1/DEGS1) to prevent conversion of dihydroceramide to ceramide; Modulation of ceramide metabolism alters apoptosis, insulin signaling, mitochondrial function, and lipid metabolism